Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
about
EGFR/HER-targeted therapeutics in ovarian cancerPotential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancerHuman beta-galactoside alpha-2,3-sialyltransferase (ST3Gal III) attenuated Taxol-induced apoptosis in ovarian cancer cells by downregulating caspase-8 activity.Niacin protects against UVB radiation-induced apoptosis in cultured human skin keratinocytesActivated epidermal growth factor receptor in ovarian cancer.Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.Design, Synthesis and Biological Evaluation of Benzohydrazide Derivatives Containing Dihydropyrazoles as Potential EGFR Kinase Inhibitors.AMP-activated protein kinase contributes to UV- and H2O2-induced apoptosis in human skin keratinocytesHCV-E2 inhibits hepatocellular carcinoma metastasis by stimulating mast cells to secrete exosomal shuttle microRNAs.Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer.NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
P2860
Q26863231-9D310407-7D39-4876-97F1-157FE0027B1AQ33511042-9D5BD06B-FAD3-4041-ACC3-093DBAF2C2F1Q33816185-36A74320-C6C5-4F08-835C-39C563B48FEFQ34253654-736768EC-3D99-4F65-ADF3-38CD083280FFQ35668911-FAA6B226-0567-44C7-A134-BD90965EEBB6Q36623820-CD2C020E-1F8A-4CC4-B994-C0289BAF3678Q36981918-2C6B0B9B-1F30-4173-A167-78787FAA11F2Q37485865-B9F63030-C091-4068-8289-54EA0E90C720Q38751733-06B5211E-0B42-400F-BD3F-D91EAEF9F566Q39948889-32662768-648B-48FF-89F7-C239C0067237Q40092894-B56061FD-0E3A-4700-B53B-82E6B8743FB2Q43131701-750E8F77-07F4-4798-B5B5-2988B452B4FCQ48095126-CBB26573-5B4E-4C4F-ACE7-99FDF99D2DB8
P2860
Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Priming with EGFR tyrosine kin ...... d to chemotherapeutical drugs.
@en
type
label
Priming with EGFR tyrosine kin ...... d to chemotherapeutical drugs.
@en
prefLabel
Priming with EGFR tyrosine kin ...... d to chemotherapeutical drugs.
@en
P2093
P2860
P1433
P1476
Priming with EGFR tyrosine kin ...... d to chemotherapeutical drugs.
@en
P2093
Ashley Amaral
Rebecca Kivlin
Wenming Chu
Yinsheng Wan
P2860
P304
P356
10.1016/J.CANLET.2008.02.062
P407
P577
2008-04-08T00:00:00Z